DuPont Merck's Coumadin
Anticoagulant warfarin receives additional indication for prevention and treatment of thromboembolic complications associated with cardiac valve replacements. Coumadin is already widely used for preventing blood clots in patients with artificial heart valves, the company notes April 25; published data indicate that long-term Coumadin therapy reduces the number of thromboembolic events in patients with heart valve replacements to less than 3%, compared to 22% in untreated patients. FDA granted the supplemental approval March 31
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth